Last reviewed · How we verify

NCT06568731

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

Completed Phase 1 Last updated 20 January 2025
What this trial tests

Phase 1 trial testing Danuglipron in Obesity in 23 participants. Completed in 18 December 2024.

Timeline
23 August 2024
Primary endpoint
18 December 2024
18 December 2024

Quick facts

Lead sponsorPfizer
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment23
Start date23 August 2024
Primary completion18 December 2024
Estimated completion18 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * about the safety and tolerability of danuglipron The total number of weeks of the study is about 15 (about 4 months).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Oral Treatment of Obesity by GLP-1 and Its Analogs.
    Holler N, Ruseska I, Schachner-Nedherer AL, Zimmer A, et al · · 2025 · PMID 41471111 · DOI 10.3390/pharmaceutics17121596

Verify or expand the search:

Other trials of Danuglipron

Trials testing the same drug.

Other recruiting trials for Obesity

Currently open trials in the same condition.

Other Pfizer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06568731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing